Two abstracts presented at the 2023 American Society of Clinical Oncology annual meeting evaluated biosimilar adoption across oncology practices and highlighted the role payers play in preventing or promoting adoption.At the end of 2022, more than half (22 of 40) of the approved biosimilars in the United States were used to treat cancer or for […]
